Nonclinical Safety Signals in PharmaPendium Improve the Predictability of Human Drug-Induced Liver Injury.

Drug-induced liver injury (DILI) is a leading cause of candidate attrition during drug development in the pharmaceutical industry. This study evaluated liver toxicity signals for 249 approved drugs (114 of "most-DILI concern" and 135 of "no-DILI concern") using PharmaPendium and assessed the association between nonclinical and clinical injuries using contingency table analysis. All animal liver findings were combined into eight toxicity categories based on nature and severity. Together, these analyses revealed that cholestasis [odds ratio (OR): 5.02; 95% confidence interval (CI) 1.04-24.03] or liver aminotransferase increases (OR: 1.86; 95% CI 1.09-3.09) in rats and steatosis (OR-1.9; 95% CI 1.03-3.49) or liver aminotransferase increases (OR-2.57; 95% CI 1.4-4.7) in dogs were significant predictors of human liver injury. The predictive value further improved when the liver injury categories were combined into less severe (steatosis, cholestasis, liver aminotransferase increase, hyperbilirubinemia, or jaundice) and more-severe (liver necrosis, acute liver failure, or hepatotoxicity) injuries. In particular, less-severe liver injuries in the following pairs of species predicted human hepatotoxicity {[dog and mouse] (OR: 2.70; 95% CI 1.25-5.84), [dog and rat] (OR-2.61; 95% CI 1.48-4.59), [monkey and mouse] (OR-4.22; 95% CI 1.33-13.32), and [monkey and rat] (OR-2.45; 95% CI 1.15-5.21)} were predictive of human hepatotoxicity. Meanwhile, severe liver injuries in both [dog and rat] (OR-1.9; 95% CI 1.04-3.49) were significant predictors of human liver toxicity. Therefore, we concluded that the occurrence of DILI in humans is highly likely if liver injuries are observed in one rodent and one nonrodent species and that liver aminotransferase increases in dogs and rats can predict DILI in humans. Together, these findings indicate that the liver safety signals observed in animal toxicity studies indicate potential DILI risk in humans and could therefore be used to prioritize small molecules with less potential to cause DILI in humans.

[1]  M. Aleo,et al.  Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms , 2021, Acta pharmaceutica Sinica. B.

[2]  M. Aleo,et al.  Most Influential Physicochemical and In Vitro Assays Descriptors for Hepatotoxicity and Nephrotoxicity Prediction. , 2020, Chemical research in toxicology.

[3]  A. D. Rodrigues,et al.  MOVING BEYOND BINARY PREDICTIONS OF HUMAN DRUG-INDUCED LIVER INJURY (DILI) TOWARDS CONTRASTING RELATIVE RISK POTENTIAL. , 2020, Chemical research in toxicology.

[4]  P. Watkins,et al.  Drug-induced liver injury , 2019, Nature Reviews Disease Primers.

[5]  M. Aleo,et al.  Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs. , 2018, Chemical research in toxicology.

[6]  Jean-Pierre Valentin,et al.  Today's Challenges to De-Risk and Predict Drug Safety in Human "Mind-the-Gap". , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  Matthew Clark,et al.  A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans , 2018, Regulatory toxicology and pharmacology : RTP.

[8]  Minjun Chen,et al.  Review article: therapeutic bile acids and the risks for hepatotoxicity , 2018, Alimentary pharmacology & therapeutics.

[9]  S. Babai,et al.  Safety data and withdrawal of hepatotoxic drugs. , 2018, Therapie.

[10]  Weida Tong,et al.  The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury , 2018, Expert review of gastroenterology & hepatology.

[11]  W. Tong,et al.  Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs , 2017, Scientific Reports.

[12]  T. Monticello,et al.  Current nonclinical testing paradigm enables safe entry to First‐In‐Human clinical trials: The IQ consortium nonclinical to clinical translational database , 2017, Toxicology and applied pharmacology.

[13]  Simon Messner,et al.  Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury , 2017, Archives of Toxicology.

[14]  T. Alempijevic,et al.  Drug-induced liver injury: Do we know everything? , 2017, World journal of hepatology.

[15]  Robert Preissner,et al.  WITHDRAWN—a resource for withdrawn and discontinued drugs , 2015, Nucleic Acids Res..

[16]  Hugh A Barton,et al.  Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[18]  Matthew Clark,et al.  Prediction of clinical risks by analysis of preclinical and clinical adverse events , 2015, J. Biomed. Informatics.

[19]  M. Aleo,et al.  Human drug‐induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump , 2014, Hepatology.

[20]  Jarrod Bailey,et al.  An Analysis of the Use of Animal Models in Predicting Human Toxicology and Drug Safety , 2014, Alternatives to laboratory animals : ATLA.

[21]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[22]  S. Shakir,et al.  An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making , 2014, BMJ Open.

[23]  Donald B Stedman,et al.  Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. , 2013, Toxicology and applied pharmacology.

[24]  Minoru Nishida,et al.  Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. , 2013, The Journal of toxicological sciences.

[25]  Weida Tong,et al.  High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury , 2013, Hepatology.

[26]  X. Chu,et al.  Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.

[27]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[28]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[29]  Y. Will,et al.  New insights in drug-induced mitochondrial toxicity. , 2011, Current pharmaceutical design.

[30]  Yvonne Will,et al.  Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry. , 2011, Current drug targets.

[31]  Yvonne Will,et al.  A high content screening assay for identifying lysosomotropic compounds. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[32]  Nigel Greene,et al.  Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. , 2010, Bioorganic & medicinal chemistry letters.

[33]  Jiri Aubrecht,et al.  Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. , 2010, Toxicology letters.

[34]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[35]  J. Xu,et al.  In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  Andrew Knight,et al.  Systematic Reviews of Animal Experiments Demonstrate Poor Human Clinical and Toxicological Utility , 2007, Alternatives to laboratory animals : ATLA.

[37]  R. Andrade,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[38]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[39]  T. Baillie,et al.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. , 2011, Drug metabolism and pharmacokinetics.

[40]  R. Wall,et al.  Are animal models as good as we think? , 2008, Theriogenology.